Abbott Labs Files 8-K on Q1 Financials

Ticker: ABT · Form: 8-K · Filed: 2024-04-17T00:00:00.000Z

Sentiment: neutral

Topics: financials, results-of-operations

Related Tickers: ABT

TL;DR

Abbott Labs dropped its Q1 2024 8-K, check the financials.

AI Summary

Abbott Laboratories filed an 8-K on April 17, 2024, reporting on its results of operations and financial condition. The filing covers the period from January 1, 2024, to March 31, 2024. Specific financial details and exhibits related to this period are included in the report.

Why It Matters

This filing provides investors with crucial, up-to-date financial information for Abbott Laboratories, impacting investment decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Abbott Laboratories' results of operations and financial condition for the period ending March 31, 2024.

What is the reporting period covered by this 8-K?

The reporting period covered by this 8-K is from January 1, 2024, to March 31, 2024.

When was this 8-K filed with the SEC?

This 8-K was filed with the SEC on April 17, 2024.

What is the principal executive office address for Abbott Laboratories?

The principal executive office address for Abbott Laboratories is 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.

Which stock exchanges is Abbott Laboratories listed on?

Abbott Laboratories is listed on the New York Stock Exchange (XNYS) and the Chicago Stock Exchange, Inc. (XCHI).

From the Filing

0001628280-24-016497.txt : 20240417 0001628280-24-016497.hdr.sgml : 20240417 20240417073602 ACCESSION NUMBER: 0001628280-24-016497 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240417 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 24849374 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20240417.htm 8-K abt-20240417 0000001800 FALSE New York Stock Exchange Chicago Stock Exchange, Inc. 0000001800 2024-01-01 2024-03-31 0000001800 exch:XCHI 2024-01-01 2024-03-31 0000001800 exch:XNYS 2024-01-01 2024-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _______________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 17, 2024 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) _______________________________________________________ Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification  No.) _______________________________________________________ 100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: ( 224 ) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition On April 17, 2024 , Abbott Laboratories announced its results of operations for the first quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, fair value adjustments to the conti

View on Read The Filing